Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Novo Nordisk is looking to partner with digital companies at every stage of the weight loss journey to help patients lose ...

As one of the important sub-sequences of "CIIE Stories", the "CIIE Babies" series will invite exhibitors from the global ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

A federal judge in Texas has upheld the U.S. Food and Drug Administration's decision to remove Novo Nordisk's blockbuster ...

Indian drug companies are preparing to launch low-cost versions of Novo Nordisk’s Wegovy and Ozempic as patents expire in 2026, making weight-loss and diabetes treatment more affordable worldwide.

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

Novo Holdings today released its Asia Investments Year in Review 2024, highlighting a year of strategic growth and ...

'Ozempic Penis' is the new side-effect that people have been turning their heads at, and users are reporting experiencing ...

A Swiss-led team has developed an AI-driven legged robot that can play badminton against human opponents, demonstrating precise coordination and accuracy. Alice Rizzo reports.

A trial pitting weight loss jab Mounjaro against competitor Wegovy ended with one clear winner, and Mounjaro is getting ...